Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and (PSOLAR)

Journal of Drugs in Dermatology

Volumn 14, Issue 7, 2015, Pages 706-714

  Papp, Kim ^a   Gottlieb, Alice B ^b   Naldi, Luigi ^c   Pariser, David ^d   Ho, Vincent ^e   Goyal, Kavitha ^f   Fakharzadeh, Steven ^f   Chevrier, Marc ^g   Calabro, Stephen ^f   Langholff, Wayne ^g   Krueger, Gerald ^h  

^a Probity Research   (Canada)

^b TUFTS MEDICAL CENTER   (United States)

^c Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g Yanssen Research and Development   (United States)

^h UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FOLLOW UP; HUMAN; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; RISK ASSESSMENT; SELF REPORT; CHEMICALLY INDUCED; MIDDLE AGED; MORTALITY; POSTMARKETING SURVEILLANCE; REGISTER; SKIN NEOPLASMS;

DERMATOLOGIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS; REGISTRIES; SKIN NEOPLASMS; USTEKINUMAB;

EID: 84941599682     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from five years of follow-up. Br J Dermatol. 2013;168:844-854.
2. Reich K, Wozel G, Zheng H, van Hoogstraten HJF, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168:1325-1334.
3. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: A comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12:321- 337.
4. Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: short- And long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67:245-256.
5. Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2013;68:756-764.
6. van Lümig PPM, van de Kerkhof PCM, Boezeman JBM, Driessen RJB, de Jong EMGJ. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Eur Dermatol Venereol. 2013;27:593-600.
7. Papp KA, Strober B, Augustin M, et al. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210-1217.
8. Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12, 095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441-1448.
9. Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics, and treatment history of patients with psoriasis enrolled in a multicenter, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014;171:137-147.
10. Dixon WG, Symmons DPM, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor a therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896-2904.
11. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035-1050.
12. Kalb RE, Fiorentino D, Lebwohl M, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: current observations in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. [Published on-line May 13, 2015] doi: 10.1001/jamadermatol.2015.0718.
13. Ryan C, Leonardi CL, Krueger JG, et al. Association between biological therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. J Am Med Assoc. 2011;306:864-871.
14. TzellosT, Kyrgidis CC, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27:622-627.
15. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses. J Am Acad Dermatol. 2013;68:863-865.
16. Krueger GG, Langley RG, Leonardi C, etal. A human-interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580- 592.
17. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;37:1665-1674.
18. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684.
19. Griffiths CEM, Strober BE, van de Kerkhof R et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-128.
20. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164:862- 872.
21. Mclnnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-789.
22. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti- IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomized PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990-999.
23. Prodanowich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262-267.
24. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: A Danish real-world cohort study. J Intern Med. 2013;273:197-204.
25. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: A cohort study. Br J Dermatol. 2011;165:1066-1073.
26. Chen Y-J, Chang Y-X, Shen J-L, et al. Association between systemic antipso- riatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: A nationwide cohort study. Arthritis Rheum. 2012;64:1879- 1887.